338 related articles for article (PubMed ID: 33594731)
21. Moderate-to-severe atopic dermatitis in different age groups treated with dupilumab in China.
Song X; Liu B; Luan T; Liao S; Tan Y; Peng C; Zhao Z
Allergy; 2023 Jun; 78(6):1696-1699. PubMed ID: 36708064
[No Abstract] [Full Text] [Related]
22. Pustular Psoriasis Appearing Induced by Dupilumab Therapy in a Patient With Atopic Dermatitis.
Jia X; Li C; Wu J; Liu Q
J Drugs Dermatol; 2022 Mar; 21(3):311-312. PubMed ID: 35254760
[TBL] [Abstract][Full Text] [Related]
23. Angioedema: A potential complication of dupilumab in atopic dermatitis.
Fritz AL; Lacy FA; Morrell DS
Pediatr Dermatol; 2021 Jan; 38(1):237-238. PubMed ID: 33099796
[TBL] [Abstract][Full Text] [Related]
24. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
25. An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab.
Tong Z; Zhang Y; Zhou K; Zou Y; Wu Z; Chen J; Zhuang Z; Zhao Y; Gong T; Ji C
J Am Acad Dermatol; 2023 Oct; 89(4):826-828. PubMed ID: 37307992
[No Abstract] [Full Text] [Related]
26. Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response.
Nettis E; Ferrucci SM; Pellacani G; Di Leo E; Argenziano G; Foti C; Rongioletti F; Patruno C; Ortoncelli M; Macchia L; Tavecchio S; Bonzano L; Di Bona D; Calabrese G; Fabbrocini G;
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e896-e898. PubMed ID: 34310749
[No Abstract] [Full Text] [Related]
27. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
[TBL] [Abstract][Full Text] [Related]
28. Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.
Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
Br J Dermatol; 2020 Jun; 182(6):e186-e209. PubMed ID: 32476149
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults.
Patruno C; Stingeni L; Hansel K; Ferrucci SM; Tavecchio S; Fabbrocini G; Nisticò SP; Foti C; De Prezzo S; Napolitano M
Dermatol Ther; 2020 May; 33(3):e13290. PubMed ID: 32125741
[TBL] [Abstract][Full Text] [Related]
30. Atopic dermatitis, dupilumab and cancers: a case series.
Siliquini N; Giura MT; Viola R; Ribero S; Panzone M; Dapavo P; Fierro MT; Ortoncelli M; Quaglino P
J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e651-e652. PubMed ID: 33797094
[No Abstract] [Full Text] [Related]
31. Success of dupilumab as a monotherapy in an adult patient affected by severe uncontrolled asthma and atopic dermatitis.
Tolino E; Proietti I; Sarni A; Bernardini N; Mambrin A; Balduzzi V; Maddalena P; Marchesiello A; Michelini S; Volpe S; Skroza N; Potenza C
Dermatol Ther; 2021 Jan; 34(1):e14596. PubMed ID: 33244860
[No Abstract] [Full Text] [Related]
32. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.
Faiz S; Giovannelli J; Podevin C; Jachiet M; Bouaziz JD; Reguiai Z; Nosbaum A; Lasek A; Ferrier le Bouedec MC; Du Thanh A; Raison-Peyron N; Tetart F; Duval-Modeste AB; Misery L; Aubin F; Dompmartin A; Morice C; Droitcourt C; Soria A; Arnault JP; Delaunay J; Mahé E; Richard MA; Schoeffler A; Lacour JP; Begon E; Walter-Lepage A; Dillies AS; Rappelle-Duruy S; Barete S; Bellon N; Bénéton N; Valois A; Barbarot S; Sénéchal J; Staumont-Sallé D;
J Am Acad Dermatol; 2019 Jul; 81(1):143-151. PubMed ID: 30825533
[TBL] [Abstract][Full Text] [Related]
34. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
Nettis E; Ferrucci SM; Ortoncelli M; Pellacani G; Foti C; Di Leo E; Patruno C; Rongioletti F; Argenziano G; Macchia L; Tavecchio S; Napolitano M; Ribero S; Bonzano L; Romita P; Di Bona D; Nisticò SP; Piras V; Calabrese G; Detoraki C; Carbonara M; Fabbrocini G
J Investig Allergol Clin Immunol; 2022 Apr; 32(2):124-132. PubMed ID: 32856595
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
[TBL] [Abstract][Full Text] [Related]
36. Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.
Yamauchi T; Sasaki S; Lee ES; Tamura T; Seki M; Miwa T; Kobayashi K; Saruta Y; Kitami Y; Sueki H; Watanabe H
Int J Dermatol; 2021 Feb; 60(2):190-195. PubMed ID: 32989751
[TBL] [Abstract][Full Text] [Related]
37. A review of dupilumab in the treatment of atopic diseases.
Thibodeaux Q; Smith MP; Ly K; Beck K; Liao W; Bhutani T
Hum Vaccin Immunother; 2019; 15(9):2129-2139. PubMed ID: 30785362
[TBL] [Abstract][Full Text] [Related]
38. Dupilumab therapy following JAK inhibitor withdrawal in moderate-severe atopic dermatitis.
Kiely L; O'Connor C; Murphy M
Dermatol Ther; 2022 Oct; 35(10):e15750. PubMed ID: 35906850
[No Abstract] [Full Text] [Related]
39. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
40. Superimposed linear atopic dermatitis treated with dupilumab.
Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
